ArticleFrontiers in oncology2025
Explorations of predictors for parametrial invasion and how it affects treatment strategy for bulky cervical cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The treatment of bulky cervical cancer (BCC) remains challenging owing to poor local control and susceptibility to distant metastasis. The study aimed to identify the factors that affect the development of parametrial invasion (PMI) and evaluate their association with different treatment modalities for BCC. Methods: The retrospective study enrolled 462 women with BCC treated at our center between January 2010 and June 2023. Logistic regression was utilized to analyze the factors influencing PMI. Kaplan-Meier method and Cox proportional hazard model were employed for survival analyses. Results: FIGO stage III-IV and primary tumor volume > 16 cm³ were identified as independent predictors for PMI in BCC, with ORs of 6.45 (95% CI 2.43-18.01) and 2.11 (95% CI 1.25-3.61), respectively. Multivariate Cox regression analysis demonstrated that the presence of PMI was associated with poorer progression-free survival (PFS) (HR 1.72, 95% CI 1.02-2.9), but exerted no significant effect on cancer-specific survival (CSS) (HR 0.86, 95% CI 0.37-2.0). The patients with FIGO stage I-II disease and no PMI who received radical surgery and adjuvant radiotherapy (RS and ART) presented improved PFS than those receiving concurrent chemoradiotherapy (CCRT), whereas CSS was unaffected. The cases at FIGO stage I-II with PMI exhibited no significant difference in PFS or CSS between receiving different treatments. No discernible difference in the incidence of grade ≥ 3 radiotherapy-related adverse events and quality of life was observed between treatment groups at 3- and 6-month post-treatment. Conclusions: BCC patients with FIGO stage III-IV and tumor volume > 16 cm
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.